Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)
Herpes Zoster, Neuralgia, Pain
About this trial
This is an interventional treatment trial for Herpes Zoster focused on measuring Analgesics, Capsaicin, Neuropathic pain, Neuropathy, PHN, Shingles
Eligibility Criteria
Summary eligibility criteria: Subjects must be in good health and have successfully completed a past trial of NGX-4010 with no past occurrence of adverse events that would contraindicate further treatment. The time between the last study patch on the previous study and the first study patch on this study must be at least 12 weeks. Topical pain medications are exclusionary and require washout prior to study patch application for this study. Chronic, nontopical pain medications are allowed but must be stable (not as needed) for a defined period prior to first study patch application. Other specific inclusion and exclusion criteria must be met prior to enrollment on the study.